Architecture, Construction, and Engineering (ACE) Industry to be Epicenter of Bio-based Epoxy Resin Market WILMINGTON, Del., Aug. 2, 2024 /PRNewswire/ — As per the latest report published by Transparency Market Research (TMR), the global bio-based epoxy resin market is estimated to reach…
Month: August 2024
Las mejoras bien pensadas mejoran las opciones y la experiencia del cliente Los nuevos modelos 3.3 Turbo Premium Sport y PHEV Premium Sport añaden diseños únicos a la gama CX-90 Más configuraciones de asientos, le permiten a los clientes personalizar mejor el CX-90 según sus necesidades…
Las mejoras bien pensadas mejoran las opciones y la experiencia del cliente Los nuevos modelos 3.3 Turbo Premium Sport y PHEV Premium Sport añaden diseños únicos a la gama CX-90 Más configuraciones de asientos, le permiten a los clientes personalizar mejor el CX-90 según sus necesidades…
Delivered Adjusted Diluted Earnings Per Share Results as Expected; Reaffirm Fiscal 2024 Adjusted Diluted EPS Outlook Progressing One Perrigo Blueprint: On Target to Deliver Project Energize Goals; Enhancing Capabilities; Completed Divestment of HRA Pharma Rare Diseases Business on July…
Delivered Adjusted Diluted Earnings Per Share Results as Expected; Reaffirm Fiscal 2024 Adjusted Diluted EPS Outlook Progressing One Perrigo Blueprint: On Target to Deliver Project Energize Goals; Enhancing Capabilities; Completed Divestment of HRA Pharma Rare Diseases Business on July…
HOUSTON and LONDON, Aug. 2, 2024 /PRNewswire/ — Second Quarter 2024 Highlights Net income: $924 million, $734 million excluding identified items(a) Diluted earnings per share: $2.82 per share; $2.24 per share excluding identified items EBITDA: $1.6 billion, $1.4 billion excluding…
HOUSTON and LONDON, Aug. 2, 2024 /PRNewswire/ — Second Quarter 2024 Highlights Net income: $924 million, $734 million excluding identified items(a) Diluted earnings per share: $2.82 per share; $2.24 per share excluding identified items EBITDA: $1.6 billion, $1.4 billion excluding…
Sugemalimab ist der weltweit erste monoklonale Anti-PD-L1-Antikörper (mAb), der in Europa für die Erstlinienbehandlung von nicht-kleinzelligem Lungenkrebs (NSCLC) mit und ohne Plattenepithelkarzinom zugelassen ist. Dies ist auch die erste erfolgreiche internationale Zulassung eines in…
Sugemalimab ist der weltweit erste monoklonale Anti-PD-L1-Antikörper (mAb), der in Europa für die Erstlinienbehandlung von nicht-kleinzelligem Lungenkrebs (NSCLC) mit und ohne Plattenepithelkarzinom zugelassen ist. Dies ist auch die erste erfolgreiche internationale Zulassung eines in…
VANCOUVER, BC, Aug. 2, 2024 /PRNewswire/ – NexGen Energy Ltd. (“NexGen” or the “Company”) (TSX: NXE) (NYSE: NXE) (ASX: NXG) is pleased to announce the Company will host its 2024 second quarter conference call on Thursday, August 8, 2024, at 8:30 am Eastern Standard Time. During the call,…